Examinando por Autor "Ortiz-Saavedra, Brando"

Mostrando 1 - 4 de 4

Acceso abierto
Antiviral Treatment against Monkeypox: A Scoping Review
(MDPI, 2022-11-10) Ortiz-Saavedra, Brando; León-Figueroa, Darwin A.; Montes-Madariaga, Elizbet S.; Ricardo-Martínez, Alex; Alva, Niza; Cabanillas-Ramirez, Cielo; Barboza, Joshuan J.; Siddiq, Abdelmonem; Coaguila Cusicanqui, Luis A.; Bonilla-Aldana, D. Katterine; Rodriguez-Morales, Alfonso J.
During the COVID-19 pandemic, the increase in reports of human monkeypox virus infection cases spreading in many countries outside Africa is a major cause for concern. Therefore, this study aimed to explore the evidence of antiviral pharmacotherapy available for the treatment of adult patients with monkeypox. A scoping review of the literature was conducted using PubMed, Scopus, Web of Science, Embase, and CENTRAL databases until 12 September 2022. The key search terms used were “monkeypox” and “treatment”. A total of 1927 articles were retrieved using the search strategy. After removing duplicates (n = 1007) and examining by title, abstract, and full text, 11 studies reporting case reports of monkeypox with antiviral treatment were included, detailing the number of monkeypox cases, clinical manifestations, number of participants with antiviral treatment, history of sexually transmitted diseases, method of diagnosis, location of skin lesions, drugs used in antiviral treatment, route of administration, and outcome. A total of 1281 confirmed cases of monkeypox have been reported, of which 65 monkeypox cases had antiviral treatment distributed most frequently in the United States (n = 30), the United Kingdom (n = 6), and Spain (n = 6). Of the total cases, 1269 (99.1%) were male with an age range of 18 to 76 years, and 1226 (95.7%) had a sexual behavior of being men who have sex with men. All confirmed cases of monkeypox were diagnosed by reverse transcriptase polymerase chain reaction (RT-PCR). The most frequent clinical manifestations were skin lesions, fever, lymphadenopathy, headache, fatigue, and myalgia. The most frequent locations of the lesions were perianal, genital, facial, and upper and lower extremities. The most commonly used drugs for antiviral treatment of monkeypox were: tecovirimat, cidofovir, and brincidofovir. All patients had a complete recovery. According to current evidence, the efficacy and safety of antiviral drugs against monkeypox is of low quality and scarce.
Acceso abierto
Antiviral Treatment against Monkeypox: A Scoping Review
(MDPI, 2022-11-10) Ortiz-Saavedra, Brando; León-Figueroa, Darwin A.; Montes-Madariaga, Elizbet S.; Ricardo-Martínez, Alex; Alva, Niza; Cabanillas-Ramirez, Cielo; Barboza, Joshuan J.; Siddiq, Abdelmonem; Coaguila Cusicanqui, Luis A.; Bonilla-Aldana, D. Katterine; Rodriguez-Morales, Alfonso J.
During the COVID-19 pandemic, the increase in reports of human monkeypox virus infection cases spreading in many countries outside Africa is a major cause for concern. Therefore, this study aimed to explore the evidence of antiviral pharmacotherapy available for the treatment of adult patients with monkeypox. A scoping review of the literature was conducted using PubMed, Scopus, Web of Science, Embase, and CENTRAL databases until 12 September 2022. The key search terms used were “monkeypox” and “treatment”. A total of 1927 articles were retrieved using the search strategy. After removing duplicates (n = 1007) and examining by title, abstract, and full text, 11 studies reporting case reports of monkeypox with antiviral treatment were included, detailing the number of monkeypox cases, clinical manifestations, number of participants with antiviral treatment, history of sexually transmitted diseases, method of diagnosis, location of skin lesions, drugs used in antiviral treatment, route of administration, and outcome. A total of 1281 confirmed cases of monkeypox have been reported, of which 65 monkeypox cases had antiviral treatment distributed most frequently in the United States (n = 30), the United Kingdom (n = 6), and Spain (n = 6). Of the total cases, 1269 (99.1%) were male with an age range of 18 to 76 years, and 1226 (95.7%) had a sexual behavior of being men who have sex with men. All confirmed cases of monkeypox were diagnosed by reverse transcriptase polymerase chain reaction (RT-PCR). The most frequent clinical manifestations were skin lesions, fever, lymphadenopathy, headache, fatigue, and myalgia. The most frequent locations of the lesions were perianal, genital, facial, and upper and lower extremities. The most commonly used drugs for antiviral treatment of monkeypox were: tecovirimat, cidofovir, and brincidofovir. All patients had a complete recovery. According to current evidence, the efficacy and safety of antiviral drugs against monkeypox is of low quality and scarce.
Acceso abierto
Epidemiologic Situation of HIV and Monkeypox Coinfection: A Systematic Review
(MDPI, 2023-11-22) Ortiz-Saavedra, Brando; Montes-Madariaga, Elizbet S.; Cabanillas-Ramirez, Cielo; Alva, Niza; Ricardo-Martínez, Alex; León-Figueroa, Darwin A.; Barboza, Joshuan J.; Mohanty, Aroop; Kumar Padhi, Bijaya; Sah, Ranjit
The most recent monkeypox (Mpox) outbreak is mostly affecting men who have sex with men (MSM) who participate in high-risk sexual behaviors, which is typically the case among human immunodeficiency virus (HIV) carriers, according to clinical and epidemiological statistics. The objective of this research is to determine the epidemiological situation of HIV and smallpox co-infection. Until 1 October 2022, a thorough evaluation of the literature was conducted utilizing the databases PubMed, Embase, Scopus, and Web of Science. Studies were evaluated based on the criteria for selection. Fifty-three studies met the selection criteria. A total of 6345 confirmed cases of monkeypox were recorded, and 40.32% (n = 2558) of these cases also had HIV co-infection. In addition, 51.36% (n = 3259) of the men (91.44%; n = 5802), whose ages ranged from 18 to 71 years, exhibited MSM-specific sexual behaviors. Co-infection with these two viruses can be especially dangerous because it can exacerbate the symptoms of both diseases and make them more difficult to treat. People with HIV are more vulnerable to certain infections, including monkeypox, because their immune systems are weakened. Therefore, it is important that they take measures to prevent infection, such as avoiding contact with infected animals, risky behaviors, and maintaining good hygiene.
Acceso abierto
“Use of Tangerine Waste as Fuel for the Generation of Electric Current“
(MDPI, 2023-02-15) Ortiz-Saavedra, Brando; Cabanillas-Chirinos, Luis; Nazario-Naveda, Renny; Gallozzo-Cardenas, Moisés; Diaz, Félix; Delfin-Narciso, Daniel; Rojas-Villacorta, Walter
“Fruit waste has increased exponentially worldwide, within which tangerine is one of those that generates a greater amount of organic waste, which is currently not fully used. On the other hand, microbial fuel cells (MFCs) are presented as an opportunity to take advantage of organic waste to generate electricity, which is why the main objective of this research is to generate bioelectricity using tangerine waste as a substrate in microbial fuel cells using zinc and copper electrodes. It was possible to generate current and voltage peaks of 1.43973 ± 0.05568 mA and 1.191 ± 0.035 V on days eighteen and seventeen, respectively, operating with an optimum pH of 4.78 ± 0.46 and with electrical conductivity of the substrate of 140.07 ± 3.51 mS/cm, while the Brix degrees gradually decreased until the last day. The internal resistance determined was 65.378 ± 1.967 Ω, while the maximum power density was 475.32 ± 24.56 mW/cm2 at a current density of 5.539 A/cm2 with a peak voltage of 1024.12 ± 25.16 mV. The bacterium (Serratia fonticola) and yeasts (Rhodotorula mucilaginosa) were identified in the substrate with an identity of 99.57 and 99.50%, respectively. Finally, the cells were connected in series, managing to generate 3.15 V, which allowed the turning on of a red LED light. “